Pediatric Blood & Cancer · 2023 · 10 citations · 27 references
MedicineOncologyChemotherapyMetastasisPediatric OncologyCancer ProgressionCancer StagingTherapy Response AssessmentTumor StagingAutologous Transplant ConditioningEastern Cooperative Oncology Group Performance StatusHigh-dose Chemotherapy AdministrationPediatric Cancer StagingPediatric Neuroblastoma ImagingResponse Capability AssessmentTandem TransplantationTransplantation
BACKGROUND: Diagnostic mIBG (meta-iodobenzylguanidine) scans are an integral component of response assessment in children with high-risk neuroblastoma. The role of end-of-induction (EOI) Curie scores (CS) was previously described in patients undergoing a single course of high-dose chemotherapy (HDC) and autologous hematopoietic cell transplant (AHCT) as consolidation therapy. OBJECTIVE: We now examine the prognostic significance of CS in patients randomized to tandem HDC and AHCT on the Children's Oncology Group (COG) trial ANBL0532. STUDY DESIGN: A retrospective analysis of mIBG scans obtained from patients enrolled in COG ANBL0532 was performed. Evaluable patients had mIBG-avid, International Neuroblastoma Staging System (INSS) stage 4 disease, did not progress during induction therapy, consented to consolidation randomization, and received either single or tandem HDC (n = 80). Optimal CS cut points maximized the outcome difference (≤CS vs. >CS cut-off) according to the Youden index. RESULTS: For recipients of tandem HDC, the optimal cut point at diagnosis was CS = 12, with superior event-free survival (EFS) from study enrollment for patients with CS ≤ 12 (3-year EFS 74.2% ± 7.9%) versus CS > 12 (59.2% ± 7.1%) (p = .002). At EOI, the optimal cut point was CS = 0, with superior EOI EFS for patients with CS = 0 (72.9% ± 6.4%) versus CS > 0 (46.5% ± 9.1%) (p = .002). CONCLUSION: In the setting of tandem transplantation for children with high-risk neuroblastoma, CS at diagnosis and EOI may identify a more favorable patient group. Patients treated with tandem HDC who exhibited a CS ≤ 12 at diagnosis or CS = 0 at EOI had superior EFS compared to those with CS above these cut points.
27
Index for rating diagnostic tests
W. J. Youden · Cancer · 1950 · 11.5K citations · Full text
Education, Educational Assessment, Educational Measurement +11
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak et al. · New England Journal of Medicine · 2010 · 1.8K citations · Full text
Medicine, Immunology, Oncology +14
Katherine K. Matthay, C. Patrick Reynolds, Robert C. Seeger et al. · Journal of Clinical Oncology · 2009 · 856 citations
Medicine, Oncology, Chemotherapy +6